FRAG 176-191 – 5mg

HGH Fragment 176-191 is a synthetic peptide spanning amino acids 176 to 191 of the C-terminal region of human growth hormone, the same sequence responsible for AOD9604’s lipolytic activity, with FRAG 176-191 representing the unmodified native fragment while AOD9604 incorporates additional stabilizing modifications. iLab Pharma’s formulation supplies 5mg as a lyophilized vial, preserving peptide structural integrity and potency across storage conditions until reconstitution. Standard practice for HGH derived peptide fragments where aqueous stability at ambient temperature is limited.

FRAG 176-191’s mechanism of action centres on selective beta-3 adrenergic receptor pathway stimulation in adipose tissue. The same receptor pathway responsible for growth hormone’s fat mobilizing effects, isolated from the IGF-1 mediated growth promoting and insulin desensitizing activity of full length HGH. By targeting only the C-terminal lipolytic sequence, FRAG 176-191 stimulates lipolysis and inhibits lipogenesis in adipose tissue without activating the growth factor receptor pathways that produce IGF-1 elevation, cellular proliferation, and insulin resistance associated with exogenous HGH administration. This selective lipolytic mechanism has made HGH fragment research compounds a frequently studied class in obesity and body composition research examining growth hormone derived peptide fragments as targeted metabolic tools.

The research distinction between FRAG 176-191 and AOD9604 is worth noting for researchers selecting between the two compounds in CSD’s HGH fragment range. Both target the same 176-191 C-terminal sequence and share the same fundamental beta-3 adrenergic lipolytic mechanism. AOD9604’s additional structural stabilisation modifications improve its metabolic stability and contributed to its FDA GRAS designation — representing the more extensively clinically characterised variant with documented human safety data. FRAG 176-191 provides the unmodified native fragment sequence as a research reference standard — valuable for comparative studies examining the effect of AOD9604’s stabilisation modifications on receptor binding, metabolic stability, and lipolytic activity relative to the base 176-191 sequence.

iLab Pharma formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD stocks both FRAG 176-191 and AOD9604 as complementary HGH fragment research compounds. Giving researchers the native unmodified sequence and the stabilization modified variant from a single verified Canadian supplier for complete comparative HGH fragment research coverage. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.

Commonly researched alongside AOD9604 and L-Carnitine in comparative lipolytic activity and body composition studies. Browse CSD’s full peptide range for complete sourcing.